Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Hsin-Ping ChiuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.ORCID 0000-0002-5010-7338
Yao Yu YeoCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-7604-2296
Tsoi Ying LaiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Chuan-Tien HungDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Shreyas KowdleDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Griffin D HaasDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Sizun JiangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.ORCID 0000-0001-6149-3142
Weina SunDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.ORCID 0000-0003-0760-1709
Funding
NHP CoreP01AI177687 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Boris Dominik Juelg · 2023 to 2026
$7.4M
Defining Mechanisms of Viral Persistence in Situ at the Single-Cell LevelR01AI149672 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI ESTES, JACOB D · 2020 to 2024
$4.0M
Spatial-Temporal Dissection of Stratified Host Tissue Responses to Severe acute respiratory syndrome-related coronaviruses in situ to Understand Intra-host PathogenesisDP2AI171139 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Sizun Jiang · 2022 to 2026
$2.3M
Human Parainfluenza Virus 3 Infection in a Novel Human Lung Tissue ModelR21AI149033 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR, LIM, JEAN KYOU · 2020 to 2021
Coronavirus (CoV) Nsp15 is a viral endoribonuclease (EndoU) with a preference for uridine residues. CoV Nsp15 is an innate immune antagonist which prevents dsRNA sensor recognition and stress granule formation by targeting viral and host RNAs. SARS-CoV-2 restricts and delays the host antiviral innate immune responses through multiple viral proteins, but the role of SARS-CoV-2 Nsp15 in innate immune evasion is not completely understood. Here, we generate an EndoU activity knockout rSARS-CoV-2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses. · full record | OpenQuestion